Mallinckrodt to sell nuclear imaging business for $690 million
Mallinckrodt PLC has agreed to sell its nuclear imaging business to IBA Molecular (IBAM) for about $690 million.
The pharmaceutical company this spring had reportedly been working with advisers on sale options for the business, which includes a portfolio of diagnostic imaging products. The deal is expected to close in the first half of next year, pending approvals by the U.S. Nuclear Regulatory Commission and Committee on Foreign Investment in the U.S., along with other clearances.
Over 800 Mallinckrodt...